Stocks / NASDAQ / Jupiter Neurosciences Inc.

Jupiter Neurosciences Inc.

Industry: Health Care – Biotechnology: Pharmaceutical Preparations

Stock Symbol: JUNS – NASDAQ

Animal Usage: Animal Testing

Our Opinion

Jupiter Neurosciences Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company confirms in corporate disclosures that it utilizes animal subjects for product testing.

“This study demonstrated the much-improved bioavailability and activity of JOTROL™ over unformulated resveratrol in an animal model of Alzheimer’s disease with extended drug exposure, stated lead author Professor Claes Wahlestedt, Associate Dean for Therapeutic Innovation, Department of Psychiatry & Behavioral Health at the University of Miami Miller School of Medicine.” Read the article for more details

Company Description

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich’s Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer’s disease. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.

Company Website: https://jupiterneurosciences.com

Contact: info@jupiterneurosciences.com